Invitation to take part in one-on-one interviews with experts ...( 36th European Association for the...)

HOME >> MEDICINE >> NEWS

Invitation to take part in one-on-one interviews with experts on Avandia

36th European Association for the Study of Diabetes (EASD) Annual Meeting, 17-21 September, 2000

On behalf of SmithKline Beecham we are delighted to be able to offer you exclusive interviews with leading experts on Avandia.

Monday 18 September, 2000
Tuesday 19 September, 2000

With the European approval of Avandia, SmithKline Beecham's new oral anti-diabetic agent, a new treatment option is available to patients with inadequately controlled type 2 diabetes.
Avandia is the first thiazolidinedione to receive centralized approval across the 15 countries of the European Union and has been approved in over 50 countries worldwide.
Avandia has been linked with improvements in -cell function and reductions in insulin resistance, both fundamental causes of type 2 diabetes.
To date, over 4 million Avandia prescriptions have been dispensed to over a million patients in the US alone.

We are delighted to be able to offer you the opportunity to interview some of the world's leading experts in diabetes in exclusive one-on-one interviews.

'"/>

Contact: Chloe Murray
chloe@meditech.co.uk
44-20-7398-0500
MediTech Media Ltd.
4-Sep-2000

Page: 1
Related medicine news :

1. Failure to count Iraqi casualties is irresponsible, say experts
2. International gathering of experts to share retinoblastoma breakthroughs
3. Injury toll in US homes tops 12 million yearly: UNC, other experts call for action
4. Assessing the season: LSU hurricane experts learned lessons during Hurricane Season 2004
5. Anniversary of one of the largest hepatitis A outbreaks in the US brings experts together
6. Rice cartilage experts win $1.5M NIH grant to bioengineer TMJ discs
7. Leading MRSA experts address emergence of superbug
8. Chest 2004 hosts world experts in pulmonary, sleep, and critical care medicine
9. Tobacco sponsorship of Formula One must stop, say health experts
10. Speech recognition experts at OGI School of Science & Engineering receive nearly $700,000 in grants
11. International experts discuss latest research on vitamin E & health

Post Your Comments:

(Date:6/19/2013)... After investing efforts for months in ... formally announced the launch of database integration for the ... latest entry in the list of extraordinary vehicles lined ... redesigned 2012 Nissan NV is all ready to get ... , Provided with two high power capable engines, the ...

(Date:6/19/2013)... Audibel Hearing Center is pleased ... patients, the A2 with Multiflex Tinnitus Technology. Tinnitus ... in the ears. Although bothersome, tinnitus usually isn’t ... , Using their patent-pending Multiflex Tinnitus Technology, the ... sound stimulus that resonates through the patient’s ear. ...

(Date:6/19/2013)... June 19, 2013 According to Vanessa ... abusers called “psychonauts” are creating new designer drugs featuring ... research of published documents and patented formulas. She reported ... & Now on June 4. , “Some of ... They’re never tested on humans. Maybe some of them ...

(Date:6/19/2013)... The Report "Data Center Security Market ... DLP, UTM, IAM, SIEM, DR, ILM); Physical Security ... Advancements, Forecasts & Analysis (2013-2018)", defines and segments ... sub-segments with in-depth analysis and forecasting of revenues. ... market with insights into trends, opportunities, and challenges. ...

(Date:6/19/2013)... Tewkesbury, UK (PRWEB) June 19, 2013 ... solutions, is sponsoring today's event, at which it will ... issues, as well as giving further insight into its ... gathering for IT & business professionals specialising in IDM ... wide range of markets including the public sector, banking, ...

Breaking Medicine News(10 mins):Health News:Rim Fitments Expert, SizeItUp Comes Up With Database Integrations For The 2012 Nissan NV 2 Health News:Audibel Hearing Center Introduces A2 with Multiflex Tinnitus Technology 2 Health News:Dangerous Designer Drugs Dodge Legal System 2 Health News:Dangerous Designer Drugs Dodge Legal System 3 Health News:Data Center Security Market is Poised to Grow at A CAGR of 16.3% & to Reach $13.77 Billion By 2018 - New Report by MarketsandMarkets 2 Health News:Data Center Security Market is Poised to Grow at A CAGR of 16.3% & to Reach $13.77 Billion By 2018 - New Report by MarketsandMarkets 3 Health News:Data Center Security Market is Poised to Grow at A CAGR of 16.3% & to Reach $13.77 Billion By 2018 - New Report by MarketsandMarkets 4

[0] Rim Fitments Expert, SizeItUp Comes Up With Database Integrations For The 2012 Nissan NV [0] Audibel Hearing Center Introduces A2 with Multiflex Tinnitus Technology [0] Dangerous Designer Drugs Dodge Legal System [0] Data Center Security Market is Poised to Grow at A CAGR of 16.3% & to Reach $13.77 Billion By 2018 - New Report by MarketsandMarkets [0] Tools4ever exhibits at Identity Management 2013

(Date:6/18/2013)... Pharmaceuticals, Inc. (NASDAQ: ISIS ), the leader in ... corporate update in conjunction with its 2013 Annual Meeting of ... p.m. Pacific Time in Carlsbad, CA. ... 2:00 p.m. – 2:10 p.m. Annual Meeting of Stockholders (only ... p.m. – 3:15 p.m. Corporate Presentation – Stanley T. ...

(Date:6/17/2013)... , June 17, 2013 Vanda ... presented additional data today at ENDO 2013, the ... that tasimelteon can entrain (synchronize) both melatonin and ... to reset the master body clock and address ... Disorder (Non-24). The SET (Safety and Efficacy of ...

(Date:6/17/2013)... 17, 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... has filed a preliminary prospectus supplement to its effective shelf ... similar filing with securities regulatory authorities in each of the ... a public offering of its common shares to raise gross ... Company will also grant to the underwriters of the Offering ...

Breaking Medicine Technology:Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House 2 Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2 Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3 Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4 Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2 Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3 Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4

[0] Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House [0] Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder [0] Valeant Pharmaceuticals Announces Public Offering Of Common Shares

Cached News:

Welcome alternative to warfarin for people at high risk of stroke Atkins-Type dieters report new cases of serious illness December 2003 Ophthalmology journal Breastfed infants show little effect when moms take anti-depressant

The smell of iron Canadian study demonstrates medical induction of labor increases risk of amniotic-fluid embolism EMEA and FDA extend drug-label based on results of the EORTC 24971 trial Should patients undergoing surgery get ASA?